SCHEMBL4301182

SCHEMBL4301182

O=C(NCc1ccc2[nH]ccc2c1)c1ccc(-c2ccccc2)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 2/20 0.59
NR1H4 Q96RI1 2/20 0.59
HDAC1 Q13547 2/20 0.58
HDAC3 O15379 1/20 0.58
HDAC4 P56524 1/20 0.58
HDAC7 Q8WUI4 1/20 0.58
HDAC2 Q92769 1/20 0.58
HDAC10 Q969S8 1/20 0.58
HDAC11 Q96DB2 1/20 0.58
HDAC8 Q9BY41 1/20 0.58
HDAC6 Q9UBN7 1/20 0.58
HDAC9 Q9UKV0 1/20 0.58
HDAC5 Q9UQL6 1/20 0.58
SMN1; SMN2 Q16637 1/20 0.56
EGFR P00533 2/20 0.54
TRPV1 Q8NER1 1/20 0.54
DRD5 P21918 1/20 0.53
MMP13 P45452 1/20 0.53
NPC1 O15118 3/20 0.53
RAB9A P51151 2/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3427153 0.90 NR1H4 (0.59) EPHX2NR1H4HDAC1HDAC3HDAC4
SCHEMBL3428967 0.87 HPGD (0.60) EPHX2SMN1; SMN2MMP13NPC1RAB9A
SCHEMBL3427971 0.85 HPGDS (0.65) EPHX2NR1H4TRPV1DRD5KLKB1
SCHEMBL3425854 0.85 NPC1 (0.56) EPHX2HDAC1HDAC3HDAC4HDAC7
SCHEMBL9764513 0.84 CTNNB1 (0.58) EPHX2NR1H4HDAC1HDAC3HDAC4
SCHEMBL3400005 0.84 HIF1A (0.53) EGFRDRD5NPC1KLKB1GSK3B
SCHEMBL3430846 0.82 CHRNA7 (0.58) EPHX2HDAC1KLKB1
SCHEMBL4301557 0.81 ALDH1A1 (0.58) EPHX2NR1H4HDAC1SMN1; SMN2MMP13
SCHEMBL3398061 0.81 EPHX2 (0.48) EPHX2HDAC1HDAC3HDAC4HDAC7
SCHEMBL3404704 0.80 EPHX2 (0.58) EPHX2NR1H4HDAC1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090270408-A1 AMIDE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS AND METHODS OF USE THEREOF ABBOTT LABORATORIES (US) 2009-10-29 US claimed
EP-2250162-B1 AMIDE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS AND METHODS OF USE THEREOF ABBVIE INC (US) 2014-03-19 EP disclosed
US-8536221-B2 Amide derivatives as positive allosteric modulators and methods of use thereof ABBVIE INC. (US) 2013-09-17 US disclosed
US-20090270408-A1 AMIDE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS AND METHODS OF USE THEREOF ABBOTT LABORATORIES (US) 2009-10-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270408-A1 AMIDE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS AND METHODS OF USE THEREOF CHRNA2, CHRNA4, CHRNA5 EPHX2 3581/4885NR1H4 1031/4885HDAC1 653/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.